Spencer, A, Lentzsch, S, Weisel, K, Avet-Loiseau, H, Mark, TM, Spicka, I, Masszi, T, Lauri, B, Levin, MD, Bosi, A, Hungria, V, Cavo, M, Lee, JJ, Nooka, AK, Quach, H, Lee, C, Barreto, W, Corradini, P, Min, CK, Scott, EC, Chanan-Khan, AA, Horvath, N, Capra, M, Beksac, M, Ovilla, R, Jo, JC, Shin, HJ
, Sonneveld, P, Soong, D, Casneuf, T, Chiu, C, Amin, H, Qi, M, Thiyagarajah, P, Sasser, AK, Schecter, JM & Mateos, MV 2018, '
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR',
Haematologica, vol. 103, no. 12, pp. 2079-2087.
https://doi.org/10.3324/haematol.2018.194118